Bots, editor, reviewer, Administrators
13,951
edits
Feed:Recent Updates: Difference between revisions
Jump to navigation
Jump to search
no edit summary
(test remove LIFE) |
No edit summary |
||
| Line 1: | Line 1: | ||
==March 2024== | ==March 2024== | ||
; [[MSLT-1]]: New summary # | ; [[LIFE]]: New summary #493: ARB vs. B-blocker in HTN with LVH | ||
; [[MSLT-1]]: New summary #492: SLNB vs. surveillance in melanoma | |||
==February 2024== | ==February 2024== | ||
; [[VITAL (Omega-3 arm)]]: New summary # | ; [[VITAL (Omega-3 arm)]]: New summary #491: Omega-3 FA for CV and cancer prevention | ||
; [[ACORN]]: New summary # | ; [[ACORN]]: New summary #490: Empiric cefepime vs. pip-tazo for infection | ||
==January 2024== | ==January 2024== | ||
| Line 11: | Line 13: | ||
==December 2023== | ==December 2023== | ||
; [[BELINDA]]: New summary # | ; [[BELINDA]]: New summary #489: Tisa-cel vs. ASCT in R/R DLBCL | ||
==November 2023== | ==November 2023== | ||
; [[SUSTAIN-6]]: New summary # | ; [[SUSTAIN-6]]: New summary #488: GLP-1 in DM if high CVD risk | ||
; [[SELECT]]: New summary # | ; [[SELECT]]: New summary #487: GLP-1 if prior CVD, BMI ≥27, no DM | ||
==October 2023== | ==October 2023== | ||
; [[LOVIT]]: New summary # | ; [[LOVIT]]: New summary #486: Vitamin C in sepsis | ||
==September 2023== | ==September 2023== | ||
; [[PROPPR]]: New summary # | ; [[PROPPR]]: New summary #485: Transfusion ratios in hemorrhagic shock | ||
; [[TOPPS]]: New summary # | ; [[TOPPS]]: New summary #484: Platelet transfusions in blood cancers | ||
; [[TXA for Epistaxis Associated with Antiplatelet Agents]]: New summary # | ; [[TXA for Epistaxis Associated with Antiplatelet Agents]]: New summary #483: TXA vs. packing for antiplatelet agent-related epistaxis | ||
==August 2023== | ==August 2023== | ||
; [[STOP-NIDDM]]: New summary # | ; [[STOP-NIDDM]]: New summary #482: Acarbose to prevent diabetes in high-risk patients | ||
==July 2023== | ==July 2023== | ||
; [[MATRIX Antithrombin]]: New summary # | ; [[MATRIX Antithrombin]]: New summary #481: Heparin vs. bivalirudin in PCI | ||
; [[GISSI-HF]]: New summary # | ; [[GISSI-HF]]: New summary #480: PUFA in patients with heart failure | ||
==June 2023== | ==June 2023== | ||
| Line 43: | Line 45: | ||
==April 2023== | ==April 2023== | ||
; [[PROPER]]: New summary # | ; [[PROPER]]: New summary #479: Validation of PERC score in PE | ||
; [[VOYAGER-PAD]]: New summary # | ; [[VOYAGER-PAD]]: New summary #478: Rivaroxaban 2.5mg BID in PAD | ||
; [[CAPE COD]]: New summary # | ; [[CAPE COD]]: New summary #477: Hydrocortisone in severe CAP | ||
==March 2023== | ==March 2023== | ||